Investment Analysts’ Recent Ratings Changes for GRAIL (GRAL)

A number of research firms have changed their ratings and price targets for GRAIL (NASDAQ: GRAL):

• 2/24/2026 – GRAIL had its price target lowered by Morgan Stanley from $110.00 to $60.00. They now have an “equal weight” rating on the stock.
• 2/20/2026 – GRAIL was given a new $82.00 price target by Robert W. Baird.
• 2/20/2026 – GRAIL had its price target lowered by Canaccord Genuity Group Inc. from $105.00 to $80.00. They now have a “buy” rating on the stock.
• 2/19/2026 – GRAIL is now covered by TD Cowen. They set a “hold” rating and a $114.00 price target on the stock.
• 2/17/2026 – GRAIL is now covered by Robert W. Baird. They set an “outperform” rating and a $113.00 price target on the stock.
• 2/17/2026 – GRAIL is now covered by Robert W. Baird. They set an “outperform” rating and a $113.00 price target on the stock.
• 1/26/2026 – GRAIL had its price target raised by Guggenheim from $100.00 to $130.00. They now have a “buy” rating on the stock.
• 1/22/2026 – GRAIL had its “sell (d-)” rating reaffirmed by Weiss Ratings.

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.